420 likes | 441 Views
I mm un e -m ed i a t e d d i sease and the M ic r o /Ma c r o b i o m e. D a v i d E . Elli o t t , M D , P hD. O u t li n e - Lea r n i ng O bject i v es. I m m u n e - m e d i a t ed d i s ea s e a n d t h e E n v i r o n m e n t B r i e f i n t o t o I m m u n e R eg u l a t i on
E N D
Immune-mediateddisease andthe Micro/Macrobiome DavidE.Elliott,MD, PhD
Outline-LearningObjectives • Immune-mediateddiseaseandtheEnvironment • BriefintotoImmuneRegulation • Micro/Macro-biomeasacontextsetter • Microbiomeanddisease • C.difficilecolitisroleofFMT • IBD • Celiac • MS • Helicobacterpylori • Pleaseinterruptandaskquestionsduringtalk • Conversationinstructsbetterthanlecture
Immune-MediatedDisease • Thereareover80well-recognizedimmune-mediateddiseases. Examplesinclude;T1D,RA,MS,Celiac,IBD,Psoriasis,Lupus,Asthma,Grave’s,ITP, … • Most areincreasingin frequencyandarerareinareaswithless industrialization. (fromBach,N.E.J.M.347:911)
InflammatoryBowelDisease NormalColon Crohn’sColitis
Normal Crohn’sDisease DysregulatedInflammation RegulatedInflammation
>160Genes/LociareImplicatedinIBDbyGWAS Both fromLeesGut60:17392011andVanLimbergenNat.Rev.Gastro/Hep11:3722014
EtiologyofIBD Nurture Nature IBD Genes Environment
“Ecologic”EventsinImmunity • GeneticpredispositionexplainsaminorcomponentoftheriskforIBD • ~50%concordanceforCrohn’sdiseasein monozygotictwins • <20%concordanceforUC inmonozygotictwin pairs • (Halfvarson,Gastroenterology124:1767) • Theimmuneresponseissensitivetocontext. ̶ ̶ ̶ ̶ Strength ofreceptorengagement(stochastic selection)Selectionofco-signalingmolecules(perceptionofdanger)Proteoglycanmatrix signals( perceptionoftissuedamage)Pre-existingcytokinemilieu(dictatesresponseprofiles) • TheMicrobiomehelpstosetimmunologiccontext
IL17 ALLERGY AUTOIMMUNITY IL21 TNF IL22 RoRt TNF IL5 IL4 IL13 IL10 IFN IL2 IL6 Th17 Th22 IL6,TGF, IL23,IL1 Th1 Th2 IL12 IL4 APC Th0 TGF IL9 Th9Tr1 TGF nTreg IL10 IL27 Th3 FoxP3 IL2 CD25+ FoxP3 Gata3 IL10 TOLERANCE ANERGY TGF
#Biomics • Current focusisonbacteria • >10,000publicationson gutmicrobiomeinlast5years • ~1000to 1200 bacterialspeciesinhabithuman gut • Each personhas~160 bacterialspeciesin gut(functionalcore) • Healthyidenticaltwinswillhavesimilarbutdifferentbacteriapopulation • Populationisrelatively stablebutcanshift–“PreBiotics” • Dysbiosis=pathologicallyskewed populationofgut bacteria • CausevsEffectofillness • (Lloyd-Price,et.al. ThehealthyhumanmicrobiomeGenomeMed8:512016) • Moreneglectedare theecologicalcontributionof: • Archaea (e.g. Methanobrevibactersmithii) • Virus(+/-RNA,ss/dsDNA,bacteriophages) • Fungi(yeast- Candida,Malassezia,andSaccharomyces) • Protozoa (Blastocystis,Entamoeba,etc...) • Helminths(worldwide50-90%of peoplecarryhelminths) • Oldfriendshypothesis–disappearingbiome
Alteringthe‘BiometoTreatImmune- MediatedInflammatoryDisease(IMID) • Assumptions: • Immunemediateddiseasesare duetoimmunedysregulation • Immunedysregulationis contextual • Themicrobiomehelpssetcontext • Changingthe‘biome maytreatdisease • Examples • C.difficilecolitis(not anIMIDbutbestexampleforbiomeRx) • IBD • Celiac • MS • Helicobacterpylori gastritis
C.difficlecolitis • Plasmid-directedproductionoftoxinsthatmediatedestructionofcolonicepithelium • Causedbyovergrowth ofClostridiumdifficileoftenafterantibiotictreatment • Treatedwithspecificantibioticsbut Clostridiaaresporeformersandrecurrentinfectionsarecommon • Recurrent/refractoryC.difficlecanbetreatedwithFecalMicrobiotaTransplant(FMT) Pseudomembranouscolitis Summitlesion
FMT–refractoryC.diff • AKA-Stooltransplant • FMTis anestablishedtreatmentforRCDI • ~92%effective (betterthanrepeatedvancomycin) • Lowerdelivery ~95%betterthanupperdelivery(~88%) • Nodifferencebetweenfreshorfrozen • Repeatedattemptsaddincrementalefficacy • Donorsneedextensivescreening • (Quraishi,et.al.Systematicreviewwithmeta-analysis:…AlimentPharmacolTher.46:4792017) • OpenBiome(commercialsourceoffrozenpoo) • Youtoocanbecomea stooldonor(Bostononly)!!!! • SynPoop-groups aretrying tocreatestandardizedculturedFM
IBD • IBDdoesnot developingerm-freeanimals • NewonsetpediatricCrohn’sdisease(668patients) • Increasedabundance(Enterobacteriaceae,Pasteurellacaea,Veillonellaceae, andFusobacteriaceae) • Decreasedabundance(Erysipelotrichales,Bacteroidales,andClostridiale) • Dysbiosisisexacerbatedbyantibiotictreatment • (Gevers,et. al.Thetreatment-naïvemicrobiomein new-onsetCrohn’sdisease.CellHostMicrobe.15:382,2014) • Othersfindsimilarchanges(dysbiosis) • CausevsEffectunknown • FMTinIBDisbeingstudied • Repeated(weeklyx6)FMT appearstobeeffectiveinUC (remission:24%FMT 5%Placebo,p=0.03) • Stooldiversityimprovedinrecipients • (Moayyedi,et. al.FecalMicrobiotaTransplantationInducesRemission in PatientsWith ActiveUlcerativeColitis…Gastroenterology149:102,2015) • –NoevidenceyetforefficacyinCrohn’s
EradicationofHookworm • JohnD.Rockefeller initiated • ~1909–SanitaryCommission • Globaleffortassistedby advancesinhygiene • DecreaseinhookworminUSAovertime • Hookwormisno longerendemicinUSA. • Hookwormcouldhelpexplainthepriornorth- south gradient.
HelminthsandtheHumanGenome • Allvertebrateanimalscarryhelminths • Carriageof helminthsappearstohaveinfluencedour genevariation • ITGAV,COL4A1,ITGA8,FLNB,ITGA9,ITGB8,ITGAM,ITGBL1,COL4A2, COL1A2,DOCK2,PTK2B,ITGAX,FYN,MAPK13,LAMA2,ITGAL,LIMS1, COL24A1,ELMO1,COL15A1,DOCK1,MAPK14,COL9A3,VAMP3,SOCS6,PLCH2,PLCB1,GRB2,GNG10,ITPR1,CXCR6,MYH14,ITGA9,MYO3B, PLA2G4B,GNAQ,CAMK2A,PLCL1,CAMK2D,ITGAM,CCR9,COL1A2, ITGB7,PAK7,VAV2,PLCD3,ADCY2,PTK2B,PLCE1,RELA,ITPR2,CCL20, PLA2G4A,COL23A1,IL4,KCNS3,CTLA4,DPP10,TLR4,PTGER2,GATA3, PHF11,IL10,NPSR1,ADRB2,IKZF2,ADRA1A, • Variationincludespathwaysconferringriskforinflammatory and autoimmunedisease (Fumagalli,BMC EvolutionaryBiology10:264,2010)
HelminthsandIBDEpidemiology • Priorhookworminfectionappearstoprotectfrom Crohn’sdisease (Kabeerdoss,Aliment.Pharmacol.Ther.;34:923,2011) • Casecontrol study in Vellore,India:75 Control/ 78 Crohn’s • Assayedin vitro PBMC reactivity tohookwormantigens • IFNELISPOT(+):48%control26%Crohn’sdisease(p<0.005) • • %CD3+CD69+shift:3.16+0.74control,0.90+0.48Crohn’s(p<0.001) • PriorhelminthexposureappearstoprotectfromIBD • (Chu,Inflamm.BowelDis.19:614,2013) • Casecontrol study in CapeTown,SouthAfrica • 88Crohn’sdisease,63ulcerativecolitis,219controls • 56%Crohn’s,66%UC patientsand91%controlsreportedchildhood helminthexposure(p<0.001) • • AdjustedOddsRatioCD=0.2[0.1-0.4], UC=0.2[0.1-0.6]
Heligmosomoides(polygyrus)bakeri • Intestinalnematodeofmice. • completelyentericlifecycle • AcquiredbyingestingsmallL3larvae. • larvaeare about0.3mmlong • Larvaeandadultwormsresideintheduodenum.
BasicH.bakeriprotocol 2 wks Sham Treatment Analyze C57BL/6 2 wks Analyze Hpb L3byGastricLavage
H.bakeriexposurealtersLPMC cytokineexpression ELISAof48hrculturesfromCD3-stimulatedcells.
H.bakeriin CD25-depletiontransfer colitisprotocol Remove CD25+ andB220+cells B6WT Spleen B6reconstitutedRag1-/- B6Rag1-/- Sham 2 wksRx Analyze Piroxicam for2wks 2 wks Analyze HpbL3 Colitic
H.bakeriexposurereverses establishedtransfercolitis 3.78±0.06 p<0.01 1.54±0.13
UlcerativeColitisTrialResults PhaseI PhaseI Response ( UCDAI>4) ChangeinUCDAIComponentScores
CeliacDisease • What is it? • Inappropriateimmuneresponsetogluten WillemKarelDicke • Glutenisatermforstorageproteinsincereal grains • Wheat,Rye,Barley • ?Oats • Delayed-type(TypeIV)hypersensitivityresponse • WheatallergyinitiallydescribedbyWillemDicke • Resultsin chronicintestinalinflammation • Allergyvs. ImmuneMediatedInflammationvs.AutoimmuneDisease
EndoscopicCharacter Celiac Normal
Normal Celiac IEL
Celiacdisease-Genetics MHCClassII&moleculesformdimersthat presentantigenstoTcells. • Morethan95%ofpatientshaveeitherHLA-DQ2(1*5011*0201)ClassIIHLA-DQ8(1*3011*0302)ClassII • About30%ofthepopulationalsoexpressthesedimers. • DQ2orDQ8arerequiredandcontributebutdonotcauseceliacdisease.
HLA-DQ2bindsglutenpeptides PQPQLPY tTG NH2 PQPELPY P=Proline Q=Glutamine L=Leucine Y=TyrosineE=Glutamate (Kim,PNAS 101:4175,2004)
5EpitopesinaPoorlyDigestible 33aaGliadinPeptide PQPQLPYPQ PYPQPQLPY ..LQLPFPQPQLPYPQPQLPYPQPQLPYPQPQPF.. P=Proline Q=Glutamine L=Leucine Y=Tyrosine F=Phenylalanine (Shan,Science297:2275,2002)
Celiacandthe‘biome • Casecontrol studyon2,933celiacpatientsmatchedwith28,262controlsfound a positivecorrelation betweenantibiotic use,and subsequentceliac(oddsratio(OR)= 1.40;CI=1.27–1.53). • (Marild,et. al. Antibioticexposureanddevelopment ofcoeliacdiseaseBMC Gastro.13:109,2013) • Duodenalbacteriafromceliacpatientsgiventogerm-freemice alterdigestionofglutentoincreaseimmunopathogenicpeptideavailability. • Pseudomonasaeruginosaseeninceliacincreasedantigenicity • Lactobacillusstrainsfromnon-celiaccontrols reducedantigenicity(Camineroet.al. (2016)Duodenalbacteriafrompatients withceliacdisease…affectgluten breakdownandimmunogenicity.Gastro.151:670,2016) • Celiacpatientshave more G-andfewG+ bacteriaandpopulationschangewithgluten-freediet
Celiacandhelminths • Investigatorsare studyingtheeffectof helminthexposureon celiacdisease. • Utilizedhookworm(Necatoramericanus) • Patientsweregiven20larvae(transdermal)andthenmicro-challenged withlow-dosegluten • Glutenexposuredidnotcauseexpectedduodenalatrophyorincrease anti-tTG,qualityoflifescoresincreased,intestinalTcellIFNγdeclined andFoxp3+Tregsincreased. • “Microbialdiversity”wasenrichedinpatientsharboringN.americanus • (Croeseet. al. ExperimentalhookworminfectionandglutenmicrochallengepromotetoleranceJ AllergyClinImmunol135:508,2015;Giacommet. al.Experimentalhookworminfection…increasedmicrobialrichnessinceliacsubjects.Sci. Reports5:13797,2015)
MultipleSclerosis(MS) • MSis causedbyimmune-mediateddestructionofinsulatingmyelininthecentralnervoussystemcausingaxon damage • Twomajorforms • Relapsing/remittingsecondaryprogressive • Primaryprogressive • Animalmodel– ExperimentalAutoimmuneEncephalitis(EAE) • Microbiome • Nomajorfindingsbutinacasecontrol study;MScasesexhibitedhigherabundancesofMethanobrevibacter(Archaea)andAkkermansiaandlowerButyricimonas • (Jangi,etal.Alterationsof thehuman gutmicrobiomeinMS. Nat.Commun. 7:12015,2016)
MSandhelminths • Casecontrolstudiessuggestthat: • Helminthcarriagereducesdiseaseseverity • (Correale,Associationbetweenparasiteinfectionandimmuneresponses inmultiplesclerosis.Ann Neurol. 61:97.2007) • Eradicationofhelminthsexacerbatesdisease • (Correale,Theimpactofparasiteinfectionson thecourseof multiplesclerosis.J.Neuroimmunol. 233:6,2011) • Therapeutichelminthexposurecanalterimmunecircuits andmayinfluencediseasecourse(open-labelstudy). • (Fleming,etal. Probiotichelminthadministrationinrelapsing-remittingmultiplesclerosis: a phase1study. MultScler.17:743,2011)
HelicobacterpyloriGastritis/Duodenitis • MotileGram(-)spiral-shapedrodbacteria • Mostcommoninfectionworldwide(>50%) • Infectionassociatedwithdecreasedsocioeconomicstatus • Prevalencevariesbyageandgroup(nextslide) • Mostinfectionsareasymptomatic
H.pylori andPUD • 2005 • DiscoveredasagentofPUD • Marshall&Warren.Lancet8390:13111984 • H.pyloricausesbothacuteandchronicgastritis • Most(~90%)ofpatientswithPUDandnotusingNSAIDshaveH.pylori. • Lifetimeriskvaries3%(US)to25%(Japan) • Hp+ NSAIDsincreasesPUDrisk60fold • EradicationofH.pylorireducesulcerrecurrence • – from~90%to10%.
H.pylori andpepticulcer disease • H.pyloridoesnotinvade(remainslumenal) • H.pylorisecretesenzymesandtoxins • AllmakeUrease • Splitsureainto bicarbonate+ NH3 • Buffersacid • MoststrainsmakeVacAandCagA • VacAcausesvacuolationofepithelialcells • CagAincreasescytokineproductionbyepithelialcells • Uncertaincontributiontopathogenicity • Immuneresponseiswhatcauses disease • –ChronicinflammationdrivesPUDandotherpathology
H.pylori –OtherIllness • AtrophicGastritis • CommoncauseofB12deficiencyintheelderly • GastricCancer(Adenocarcinoma) • H.pyloriisclassifiedasType1(definite)carcinogen • Themajorcauseofgastriccancerworldwide • MALTLymphoma(98%haveH.pylori) • MALT = Mucosa-associatedLymphoidTissue • B-celltumorinfiltratingthegastricmucosa • About80%regresswithH.pylorieradication
H.pylori diagnosis/treatment • Diagnosis • Serology(IgGAnti-Hpantibody) • Best screeningtestif on PPI • Remains+ for~2yrs afterRx • Ureasebreathtest • StoolAgtest • Gastricbiopsy(evaluationofPUD) Giemsa,KacarInternetJournalofPathology.3:2004 • Histology • urease“CLO”testing • Treatment • Iffound–> treat. • Eradicationrateisabout75% • Triple therapy(PPI+2antibioticsfor2weeks) • ClarithromycinplusAmpicillinorMetronidazole
HelicobacterpyloriMicrobiome • Eradication hasnoeffectongeneraldiversitybut • reducesrelativeabundanceofBacterioidetes • withcorrespondingincreaseinFirmicutes • (Wan-ChenYap,etal.Helicobacter pyloriEradicationCausesPerturbationof the HumanGutMicrobiomeinYoungAdults. PlosOne11:e0151893,2016) • Otherbacteriainhabitthestomach • H.pyloripathologymaybe influencedbyotherbugs • (ShehTheroleof thegastrointestinalmicrobiomein Helicobacterpyloripathogenesis.GutMicrobes.4:505,2013) • HelminthinfectionaltersH.pylori pathologyandmay decreasecancerrisk • (Ek, et al. Serologicevidencethatascarisandtoxoplasmainfectionsimpactinflammatoryresponses toHelicobacterpyloriinColombians.Helicobacter.17:107-15,2012)